Beam Therapeutics Inc (NYSE: BEAM) — Company Overview, News & Financial Data
Beam Therapeutics develops precision genetic medicines through base editing for serious genetic diseases.
Beam Therapeutics Inc
Beam Therapeutics (NASDAQ:BEAM) is at the forefront of developing precision genetic medicines through base editing, a groundbreaking approach to genome editing that enables precise, predictable, and efficient single base changes without making double-stranded breaks in the DNA. This innovative technology has the potential to overcome many of the limitations associated with conventional genome editing methods, offering new possibilities for treating a wide range of genetic diseases. The company's pipeline encompasses projects targeting serious conditions such as sickle cell disease, beta thalassemia, and certain eye disorders, demonstrating its commitment to addressing unmet medical needs. Beam's objective is to leverage its cutting-edge platform to create a new class of genetic medicines that can provide life-long cures to patients suffering from serious diseases.
Snapshot
Operations
Products and/or services of Beam Therapeutics Inc
- Development of base editing, a precision gene editing technology that enables the direct, irreversible conversion of a target DNA base into another, offering a less error-prone alternative to CRISPR-Cas9.
- BEAM-101, aimed at treating sickle cell disease by performing precise edits on the HBB gene in hematopoietic stem cells to elevate fetal hemoglobin levels.
- BEAM-102, designed for the treatment of beta-thalassemia, focuses on editing the HBG1 and HBG2 promoters in hematopoietic stem cells to increase fetal hemoglobin expression.
- BEAM-201, a project targeting T-cell malignancies by editing CAR-T cells to enhance their cancer-fighting capabilities and potentially increasing their safety and efficacy.
- Pipeline expansion into liver diseases, utilizing base editing to precisely correct disease-causing mutations in hepatocytes, offering potential treatments for a variety of genetic liver disorders.
- Investment in next-generation base editing technologies to expand the scope and efficiency of current gene editing capabilities, aiming to create more versatile and precise therapies.
Beam Therapeutics Inc executive team
- John M. EvansCEO & Director
- Giuseppe CiaramellaPresident
- Sravan Kumar EmanyChief Financial Officer
- Christine P. BellonChief Legal Officer & Corporate Secretary
- Amy SimonChief Medical Officer
- Feng ZhangCo-Founder
- David R. LiuCo-Founder
- J. Keith JoungCo-Founder
- Bethany J. CavanaghSenior VP of Finance, Treasurer & Principal Accounting Officer
- Manmohan SinghChief Technology Officer
Latest news about Beam Therapeutics Inc
Beam reports AATD therapy trial update
United StatesPrime Medicine secures decisive binding arbitration victory
United StatesBeam Therapeutics receives FDA clearance for BEAM-304
United StatesBeam Therapeutics bolsters cash position to $1.25B with new $500M facility
United StatesBeam Therapeutics extends cash runway to 2028 following major clinical milestones
United States
Key financials
Reported results for Beam Therapeutics Inc, in USD.
- Market cap
- 3B
- Revenue (TTM)
- 156M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.7
- Dividend yield
- —
- Profit margin
- -55.5%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 139.7M | -383.7M | -80M | |
| 63.5M | -415.6M | -376.7M | |
| 377.7M | -176.5M | -132.5M | |
| 60.9M | -338.5M | -289.1M |